Physician profile
Kingman P Strohl
NPI 1053331124
$9,707.60
in general payments reported to CMS, 2019-2025
12 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $1,225 · 2021: $4,771 · 2022: $1,004 · 2023: $1,095 · 2024: $175 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222 · Consulting Fee: $400 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.74 |
| Consulting Fee | $400.00 |
| Education | $149.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $4,250.00 | 2021 | |
| Merck Sharp & Dohme LLC | $2,917.09 | 2019-2023 | Dificid, Zerbaxa |
| Inspire Medical Systems, INC. | $1,140.67 | 2019-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $706.83 | 2020-2025 | |
| Harmony Biosciences LLC | $421.62 | 2022-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $119.48 | 2024-2025 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $74.23 | 2022-2023 | Breztri, Tezspire, Airsupra |
| Teva Pharmaceuticals USA, INC. | $17.28 | 2023 | Airduo Digihaler |
| Electromed, INC. | $17.28 | 2023 | Smartvest |
| Mylan Specialty L.P. | $16.58 | 2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.72 | 2023 | Xifaxan |
| 3b Medical, INC. | $12.82 | 2023 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kingman Strohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.